Literature DB >> 12883080

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the regulation and posttranslational modification of p27kip1 in lipopolysaccharide-activated B cells.

Robert B Crawford1, Courtney E W Sulentic, Byung S Yoo, Norbert E Kaminski.   

Abstract

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters B-cell differentiation, as evidenced by a marked decrease in immunoglobulin M (IgM) secretion and in the number of antibody-forming cells (AFC) induced by antigenic stimulation. The objective of the present studies was to evaluate the effect of TCDD on the level of p27kip1, a cyclin-dependent kinase inhibitor that is a critical regulator of cellular differentiation. In the well-characterized B-cell line, CH12.LX, a modest decrease in p27kip1 was observed during the initial 24-h post-LPS (lipopolysaccharide) activation, which then gradually increased above background at 48 and 72 h. Conversely, in the presence of TCDD, p27kip1 was not induced and remained unchanged from LPS unstimulated cells throughout the entire 72-h period post-LPS activation. In addition, Western blotting revealed that TCDD treatment altered the profile of p27kip1 migration as compared to the LPS-activated control. Time-of-addition studies demonstrated that the greatest sensitivity of p27kip1 to TCDD treatment occurred within the initial 24-h post-LPS activation. Interestingly, LPS-induced Ig kappa light chain and IgM secretion also exhibited the greatest period of sensitivity (i.e., inhibition) to TCDD during the first 24-h post-LPS activation. In addition, TCDD markedly suppressed the LPS-induced differentiation of CH12.LX cells into IgM secreting AFC, with a modest but cumulative effect on cell proliferation over a 72-h period. Collectively, these findings show that TCDD altered the cellular concentration and posttranslational modification of p27kip1 in this activated B-cell line model, which occurred concomitantly with altered B-cell differentiation and suggests that cyclin-dependent kinase inhibitors may be an important intracellular target in TCDD-mediated inhibition of B-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883080     DOI: 10.1093/toxsci/kfg199

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  8 in total

1.  The Influence of Human Interindividual Variability on the Low-Dose Region of Dose-Response Curve Induced by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Primary B Cells.

Authors:  Peter Dornbos; Robert B Crawford; Norbert E Kaminski; Sarah L Hession; John J LaPres
Journal:  Toxicol Sci       Date:  2016-07-29       Impact factor: 4.849

2.  Role of aryl hydrocarbon receptor polymorphisms on TCDD-mediated CYP1B1 induction and IgM suppression by human B cells.

Authors:  Natalia Kovalova; Maria Manzan; Robert Crawford; Norbert Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2016-08-14       Impact factor: 4.219

Review 3.  The long winding road toward understanding the molecular mechanisms for B-cell suppression by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  Courtney E W Sulentic; Norbert E Kaminski
Journal:  Toxicol Sci       Date:  2010-10-15       Impact factor: 4.849

4.  Disruption of human plasma cell differentiation by an environmental polycyclic aromatic hydrocarbon: a mechanistic immunotoxicological study.

Authors:  Lenka L Allan; David H Sherr
Journal:  Environ Health       Date:  2010-03-24       Impact factor: 5.984

5.  Stochastic modeling of B lymphocyte terminal differentiation and its suppression by dioxin.

Authors:  Qiang Zhang; Sudin Bhattacharya; Douglas E Kline; Robert B Crawford; Rory B Conolly; Russell S Thomas; Norbert E Kaminski; Melvin E Andersen
Journal:  BMC Syst Biol       Date:  2010-04-01

6.  All-or-none suppression of B cell terminal differentiation by environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  Qiang Zhang; Douglas E Kline; Sudin Bhattacharya; Robert B Crawford; Rory B Conolly; Russell S Thomas; Melvin E Andersen; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2013-01-26       Impact factor: 4.219

7.  Ah receptor antagonism represses head and neck tumor cell aggressive phenotype.

Authors:  Brett C DiNatale; Kayla Smith; Kaarthik John; Gowdahalli Krishnegowda; Shantu G Amin; Gary H Perdew
Journal:  Mol Cancer Res       Date:  2012-08-21       Impact factor: 5.852

8.  Aryl hydrocarbon receptor-induced activation of the human IGH hs1.2 enhancer: Mutational analysis of putative regulatory binding motifs.

Authors:  Andrew D Snyder; Sharon D Ochs; Brooke E Johnson; Courtney E W Sulentic
Journal:  Mol Immunol       Date:  2020-03-06       Impact factor: 4.407

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.